Abstract: The present disclosure relates to semiconductor structures and, more particularly, to a buffered thin film resistor (TFR) with metal-insulator-metal (MIM) capacitor integration and methods of manufacture. The structure includes: a first buffer contact on a substrate; a second buffer contact on the substrate, the second buffer contact being on a same wiring level as the first buffer contact; a stack of resistive thin films contacting the first buffer contact and the second buffer contact, the stack of resistive thin films extending on the substrate between the first buffer contact and the second buffer contact; and electrical contacts that are in physical contact to a top plate of the stack of resistive thin films.

Abstract: A method of administering, to a tympanic cavity, a pharmaceutical composition using a drug delivery device implanted through a tympanic membrane, the method including fluidly connecting the drug delivery device to an injection system via an inlet of a flexible catheter of the drug delivery device; and introducing, to the tympanic cavity, a volume of the pharmaceutical composition via the drug delivery device.

Abstract: The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.

Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.

Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with a mutation in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein (e.g., an OTOF isoform 5 protein) and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein (e.g., an OTOF isoform 5 protein). These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.

Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.

Abstract: The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.

Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.

Abstract: The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus genome. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.

Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.

Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.

Abstract: A fishing line spooler configured to engage a shaft of a fishing rod. The fishing line spooler includes a clamp selectively securable to the shaft of the fishing rod and a mounting shaft. The mounting shaft receives a fishing line supply spool along its length. The supply spool is configured to rotate around the mounting shaft. The mounting shaft is selectively mountable to the clamp in a first orientation or a second orientation. In the first orientation, the mounting shaft is secured to the clamp parallel to the longitudinal axis of the fishing rod and feeds a spinning reel. In the second orientation, the mounting shaft is secured to the clamp perpendicular to the longitudinal axis of the fishing rod and feeds a casting reel.

Abstract: The invention provides methods to prepare protein conjugates from proteins having at least two cysteines. In one embodiment, a protein with a disulfide linkage is reduced to provide two free cysteines for reaction with a 1,3-dihaloacetone or similar reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form a Schiff base to an aminated payload molecule, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant. The linkage between the sulfur atoms in each case holds the protein or peptide in a constrained conformation, while also providing a convenient place for attaching a payload with good specificity and efficiency.

Abstract: The invention provides compositions and methods containing alpha-helical polypeptides as permeation enhancers for effectuating the passage of therapeutic agents into the inner ear by passage through the round window membrane. Examples of permeation-enhancing peptides useful in conjunction with the compositions and methods described herein are facially amphipathic, positively charged peptides. The permeation-enhancing peptides of the disclosure may be used to effectuate the entry of a variety of therapeutic agents into the inner ear, such as proteins, antibodies, nucleic acids, viral vectors, and nanoparticles, among others. Upon accessing the inner ear, the therapeutic agents may migrate to a particular site at which they may exert their biological effect.

Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.

Abstract: This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.

Abstract: This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.

Abstract: Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions.

Abstract: A fishing line spooler configured to engage a shaft of a fishing rod. The fishing line spooler includes a clamp selectively securable to the shaft of the fishing rod and a mounting shaft. The mounting shaft receives a fishing line supply spool along its length. The supply spool is configured to rotate around the mounting shaft. The mounting shaft is selectively mountable to the clamp in a first orientation or a second orientation. In the first orientation, the mounting shaft is secured to the clamp parallel to the longitudinal axis of the fishing rod and feeds a spinning reel. In the second orientation, the mounting shaft is secured to the clamp perpendicular to the longitudinal axis of the fishing rod and feeds a casting reel.

Abstract: Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.